AU728512B2 - Method for preventing HIV-1 infection of CD4+ cells - Google Patents

Method for preventing HIV-1 infection of CD4+ cells Download PDF

Info

Publication number
AU728512B2
AU728512B2 AU26074/97A AU2607497A AU728512B2 AU 728512 B2 AU728512 B2 AU 728512B2 AU 26074/97 A AU26074/97 A AU 26074/97A AU 2607497 A AU2607497 A AU 2607497A AU 728512 B2 AU728512 B2 AU 728512B2
Authority
AU
Australia
Prior art keywords
chemokine
hiv
agent
cell
peptidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26074/97A
Other languages
English (en)
Other versions
AU2607497A (en
Inventor
Graham P. Allaway
Virginia M. Litwin
Paul J. Maddon
William C. Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of AU2607497A publication Critical patent/AU2607497A/en
Application granted granted Critical
Publication of AU728512B2 publication Critical patent/AU728512B2/en
Priority to AU35106/01A priority Critical patent/AU776239B2/en
Priority to AU2004233505A priority patent/AU2004233505B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU26074/97A 1996-04-02 1997-04-02 Method for preventing HIV-1 infection of CD4+ cells Ceased AU728512B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU35106/01A AU776239B2 (en) 1996-04-02 2001-04-10 Method for preventing HIV-1 infection of CD4+ cells
AU2004233505A AU2004233505B2 (en) 1996-04-02 2004-11-26 Method for preventing HIV-1 infection of CD4+ cells

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62768496A 1996-04-02 1996-04-02
US08/627684 1996-04-02
US66361696A 1996-06-14 1996-06-14
US08/663616 1996-06-14
US67368296A 1996-06-25 1996-06-25
US08/673682 1996-06-25
PCT/US1997/005597 WO1997037005A1 (en) 1996-04-02 1997-04-02 Method for preventing hiv-1 infection of cd4+ cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU35106/01A Division AU776239B2 (en) 1996-04-02 2001-04-10 Method for preventing HIV-1 infection of CD4+ cells

Publications (2)

Publication Number Publication Date
AU2607497A AU2607497A (en) 1997-10-22
AU728512B2 true AU728512B2 (en) 2001-01-11

Family

ID=27417425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26074/97A Ceased AU728512B2 (en) 1996-04-02 1997-04-02 Method for preventing HIV-1 infection of CD4+ cells

Country Status (5)

Country Link
EP (1) EP0915969A4 (enExample)
JP (2) JP2000507596A (enExample)
AU (1) AU728512B2 (enExample)
CA (1) CA2250829A1 (enExample)
WO (1) WO1997037005A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
ES2270461T3 (es) * 1996-06-03 2007-04-01 United Biomedical, Inc. Anticuerpos contra un complejo de cd4 y un dominio receptor de quemoquina, y sus usos contra las infecciones de vih.
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
FR2771423A1 (fr) * 1997-11-21 1999-05-28 Transgene Sa Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
US6399078B1 (en) 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
DE60041489D1 (de) * 1999-07-09 2009-03-19 Gen Probe Inc Nachweis von hiv-1 durch amplifizierung von nukleinsäuren
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
EP2053060A1 (en) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
CA2922428A1 (en) 2013-08-29 2015-03-05 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for rna-guided treatment of hiv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
EP0854918A1 (en) * 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
EP0883687B1 (en) 1996-03-01 2004-10-27 Euroscreen S.A. C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih

Also Published As

Publication number Publication date
EP0915969A4 (en) 2002-04-17
EP0915969A1 (en) 1999-05-19
AU2607497A (en) 1997-10-22
CA2250829A1 (en) 1997-10-09
JP2000507596A (ja) 2000-06-20
WO1997037005A1 (en) 1997-10-09
JP2008069148A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
US6344545B1 (en) Method for preventing HIV-1 infection of CD4+ cells
AU753362B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU735460B2 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
WO1997037005A1 (en) Method for preventing hiv-1 infection of cd4+ cells
Nibbs et al. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity
Dragic et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Frade et al. The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection.
Simmons et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands
Willett et al. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses
Burns et al. A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling
WO1995019436A1 (en) Mammalian monocyte chemoattractant protein receptors
US20040086528A1 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
US7935797B2 (en) CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion
AU776239B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU2004233505B2 (en) Method for preventing HIV-1 infection of CD4+ cells
HK1029520B (en) Method for preventing hiv-1 infection of cd4+ cells
JP4116087B2 (ja) 新規マウスｃｘｃケモカインレセプター
AU2004205143A1 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
MXPA98010425A (en) Uses of a chemiocine receiver to inhibit theinfection with human immunodeficiency viruses
Simmons Human immunodeficiency virus type 1 cell tropism and inhibition by chemokines and chemokine analogues
JPWO1998035035A1 (ja) 新規マウスｃｘｃケモカインレセプター
Combadiere et al. Identification of CX3CR1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)